CORDIS announces results of ten-year CYPHER sirolimus-eluting coronary stent follow-up


Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, have announced at European Society of Cardiology (ESC) in Stockholm that the results of follow-up tests undertaken ten years after the first patient was treated with a CYPHER sirolimus-eluting coronary stent have proven outstanding long-term efficacy and safety.


The 85-year-old was the first-ever patient to be treated with a CYPHER stent and made history by undergoing the longest term follow-up – the procedure broadcast live during the 2009 meeting of the Latin America Society of Interventional Cardiology (SOLACI, Rio de Janeiro – Brazil) – ten years later. The results of the follow-up were published earlier this year in “JACC: Cardiovascular Interventions”.


The patient was first treated in 1999 with the CYPHER stent at the age of 75 after her coronary angiography showed a significant, single, de novo lesion in the proximal left anterior descending (LAD) artery. She then under-went further invasive follow-up revealing a sustained anti-proliferative effect of the CYPHER stent by both angiography and IVUS examination in 2009. The patient also underwent an optical coherence tomography (OCT) assessment which revealed a complete coverage of over 90% of the analysed struts.


Professor Eduardo Sousa, who led the team carrying out the first-in-human trial in 1999 and the ten-year follow-up tests in 2009 in Sao Paolo, Brazil, said, “We are very pleased with these results. This historic follow-up has revealed a sustained anti-proliferative effect of the CYPHER stent by both angiography (in-stent late lumen loss of 0.10mm at 9 months as compared to 0.11 at 48 months) and IVUS examination (in stent % of obstruction of 1% at 4 months and 1,2,4, and 9 years). This is an impressive outcome and a testament to the efficacy of the CYPHER stent.”


This ten-year follow-up of the first-ever patient to be treated with CYPHER continues a tradition of comprehensive testing for the most studied drug-eluting stent in the world, reinforcing the CYPHER sirolimus-eluting coronary stent’s reputation for efficacy and safety.


Campbell Rogers, chief scientific officer and global head R&D at Cordis, said, “We continue to be gratified by the outstanding performance of CYPHER compared with other drug-eluting stents. The breadth of clinical safety and efficacy data and the long-term follow-up data on patient outcomes associated with the CYPHER stent are unmatched by the competition. These historic long term results with the CYPHER stent join ever-growing datasets demonstrating superiority of the CYPHER Stent over other newer DES competitors in diverse patient and lesion subsets and establish CYPHER stent as the gold standard treatment for patients with coronary disease undergoing PCI.”